Download PDF
Thromb Haemost 1992; 67(05): 533-536
DOI: 10.1055/s-0038-1648488
Original Articles
Schattauer GmbH Stuttgart

In Vivo Significance of Kinetic Constants of Tight Binding Reversible Proteinase Inhibitors

Colin Longstaff
The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, UK
› Author Affiliations
Further Information

Publication History

Received 26 July 1991

Accepted after revision 08 November 1991

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

For a reaction between an enzyme and inhibitor, rate constants and equilibrium constants are both widely used as measures of inhibitor potency. Which one of these two parameters should be used depends on the mechanism of the reaction. Moreover, for biological studies it is not always the overall effectiveness of an inhibitor that is important, but also the rate at which it acts in conditions that may be encountered in vivo. In vitro investigations may be performed to determine the kinetic and thermodynamic constants in an enzyme inhibitor system and to investigate the influence of various other effector biomolecules. However, in translating these results into physiological conclusions, care must be taken that the in vitro experiments have been properly designed and data analysed correctly. This article is an attempt to indicate some of the problems that can be encountered in this process.

 

  • References

  • 1 Beith JE. In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med 1984; 32: 387-397
    CrossrefPubMedGoogle Scholar
  • 2 Morrison JF, Walsh CT. The behaviour and significance of slow-binding enzyme inhibitors. Adv Enzymol 1988; 61: 201-301
    PubMedGoogle Scholar
  • 3 Morrison JF. The slow-binding and slow tight-binding inhibition of enzyme-catalysed reactions. Trends Biochem Sci 1982; 7: 102-105
    CrossrefPubMedGoogle Scholar
  • 4 Salvesen G, Nagase H. Inhibition of proteolytic enzymes. In: >Proteolytic Enzymes a Practical Approach. Beynon RJ, Bond JS. (eds) Oxford University Press; Oxford: 1989. pp 83-104
    Google Scholar
  • 5 Laskowski Jr M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626
    CrossrefPubMedGoogle Scholar
  • 6 Longstaff C, Campbell AF, Fersht AR. Recombinant chymotrypsin inhibitor 2. Expression, kinetic analysis of inhibition with a-chymo-trypsin and wild-type and mutant subtilisin BPN’, and protein engineering to investigate specificity and mechanism. Biochemistry 1990; 29: 7339-7347
    CrossrefPubMedGoogle Scholar
  • 7 Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: a2-antiplasmin as a model inhibitor. Biochemistry 1991; 30: 979-986
    CrossrefPubMedGoogle Scholar
  • 8 Shieh B-H, Potempa J, Travis J. The use of a2-antiplasmin as a model for the demonstration of complex reversibility in serpins. J Biol Chem 1989; 264: 13420-13423
    Google Scholar
  • 9 Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, protein-ase-complexed and reactive site cleaved serpins. Comparison of ax-proteinase inhibitor, ai-antichymotrypsin, antithrombin III, a2-anti-plasmin, angiotensinogen and ovalbumin. Biochemistry 1991; 30: 1723-1730
    CrossrefPubMedGoogle Scholar
  • 10 Matheson NR, van Halbeck H, Travis J. Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions. J Biol Chem 1991; 266: 13489-13491
    Google Scholar
  • 11 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709
    CrossrefPubMedGoogle Scholar
  • 12 Read RJ, James MNG. Introduction to the protein inhibitors: X-ray crystallography. In: Proteinase Inhibitors. Barret AJ, Salvesen G. (eds) Elsevier; Amsterdam: 1986. pp 301-336
    Google Scholar
  • 13 Fersht AR. Enzyme Structure and Mechanism. 2nd ed. Freeman; New York: 1984
    Google Scholar
  • 14 Cha S. Tight-binding inhibitors-I. Kinetic behaviour. Biochem Pharmacol 1975; 24: 2177-2186
    CrossrefPubMedGoogle Scholar
  • 15 Jesty J. The kinetics of formation and dissociation of the bovine thrombin-antithrombin III complex. J Biol Chem 1979; 254: 10044-10050
    PubMedGoogle Scholar
  • 16 Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-1737
    CrossrefPubMedGoogle Scholar
  • 17 Lennick M, Brew SA, Ingham KC. Kinetics of Interaction of Cl Inhibitor with Complement Cls. Biochemistry 1986; 25: 3890-3898
    CrossrefPubMedGoogle Scholar
  • 18 Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-121
    CrossrefPubMedGoogle Scholar
  • 19 Holmes WE, Lijnen HR, Nelle L, Kluft C, Nieuwenhuis HK, Rijken DC, Collen D. a2-Antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science 1987; 6238: 209-211
    PubMedGoogle Scholar
  • 20 Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin, ax-Antitrypsin Pittsburgh (358 Met —> Arg), a fatal bleeding disorder. N Engl J Med 1983; 309: 694-698
    CrossrefPubMedGoogle Scholar